Mild photothermal therapy/photodynamic therapy/chemotherapy of breast cancer by Lyp-1 modified Docetaxel/IR820 Co-loaded micelles

Li, Wenting; Peng, Jinrong; Tan, Liwei; Wu, Jing; Shi, Kun; Qu, Ying; Wei, XiaWei; Zhang, Qian

doi:10.1016/j.biomaterials.2016.08.016

Cited by 216 publications

(154 citation statements)

References 28 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Because of these drawbacks, it is obvious that chemotherapy alone faces challenges, and a new approach is needed in order to achieve a satisfactory outcome in cancer patients. Therefore, combination therapy has emerged as a new and effective strategy capable of overcoming the limitations of chemotherapy 5. It is suggested that the association of common chemotherapeutic agents with existing anticancer agents, new ones or even natural products, could maximize the chemotherapy efficacy and reduce the toxic effects to normal cells.…”

Section: Introductionmentioning

confidence: 99%

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

Tefas

Sylvester

Tomuță

et al. 2017

DDDT

114

View full text Add to dashboard Cite

The aim of this work was to use the quality-by-design (QbD) approach in the development of long-circulating liposomes co-loaded with curcumin (CUR) and doxorubicin (DOX) and to evaluate the cytotoxic potential of these liposomes in vitro using C26 murine colon carcinoma cell line. Based on a risk assessment, six parameters, namely the phospholipid, CUR and DOX concentrations, the phospholipid:cholesterol molar ratio, the temperature during the evaporation and hydration steps and the pH of the phosphate buffer, were identified as potential risk factors for the quality of the final product. The influence of these variables on the critical quality attributes of the co-loaded liposomal CUR and DOX was investigated: particle size, zeta potential, drug loading and entrapment efficiency. For this, a 26−2 factorial design was employed to establish a proper regression model and to generate the contour plots for the responses. The obtained data served to establish the design space for which different combinations of variables yielded liposomes with characteristics within predefined specifications. The validation of the model was carried out by preparing two liposomal formulations corresponding to the robust set point from within the design space and one outside the design space and calculating the percentage bias between the predicted and actual experimental results. The in vitro antiproliferative test showed that at higher CUR concentrations, the liposomes co-encapsulating CUR and DOX had a greater cytotoxic effect than DOX-loaded liposomes. Overall, this study showed that QbD is a useful instrument for controlling and optimizing the manufacturing process of liposomes co-loaded with CUR and DOX and that this nanoparticulate system possesses a great potential for use in colon cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

Tefas

Sylvester

Tomuță

et al. 2017

DDDT

114

View full text Add to dashboard Cite

show abstract

“…24,25 Due to its good biosecurity, IR820 was employed as the photothermal agent in this study. 26,27 To further improve the theranostic efficiency and provide a way to image the pathological characteristics of tumors, it is necessary to develop a more effective theranostic agent to sense subtle pathological changes. The lipid-polymer hybrid nanoparticles, which have various advantages of polymeric nanoparticles and liposomes, have become a robust delivery platform with properties such as excellent stability, tunability, high drug encapsulation, and sustained drug release.…”

Section: Introductionmentioning

confidence: 99%

Near-infrared light-triggered theranostics for tumor-specific enhanced multimodal imaging and photothermal therapy

Wu¹,

Wang²,

Lu³

et al. 2017

IJN

View full text Add to dashboard Cite

The major challenge in current clinic contrast agents (CAs) and chemotherapy is the poor tumor selectivity and response. Based on the self-quench property of IR820 at high concentrations, and different contrast effect ability of Gd-DOTA between inner and outer of liposome, we developed “bomb-like” light-triggered CAs (LTCAs) for enhanced CT/MRI/FI multimodal imaging, which can improve the signal-to-noise ratio of tumor tissue specifically. IR820, Iohexol and Gd-chelates were firstly encapsulated into the thermal-sensitive nanocarrier with a high concentration. This will result in protection and fluorescence quenching. Then, the release of CAs was triggered by near-infrared (NIR) light laser irradiation, which will lead to fluorescence and MRI activation and enable imaging of inflammation. In vitro and in vivo experiments demonstrated that LTCAs with 808 nm laser irradiation have shorter T 1 relaxation time in MRI and stronger intensity in FI compared to those without irradiation. Additionally, due to the high photothermal conversion efficiency of IR820, the injection of LTCAs was demonstrated to completely inhibit C6 tumor growth in nude mice up to 17 days after NIR laser irradiation. The results indicate that the LTCAs can serve as a promising platform for NIR-activated multimodal imaging and photothermal therapy.

show abstract

“…In terms of tumor-targeted delivery, a suitable delivery system is required that helps this combination escape from the recognition of macrophage systems, penetrate into tumor tissues, and accumulate in their intracellular sites of action. In recent years, significant progress in combination therapy has been made with cationic nanoparticles formed with liposomes, 26,27 polymers, 28,29 micelles, 30,31 and dendrimers. 29 Among these, endogenous lipoproteins have attracted growing attention, due to their advantages, such as ease of formulation, excellent biocompatibility, and clinical potential.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells

Rui¹,

Qu²,

Gao³

et al. 2016

IJN

View full text Add to dashboard Cite

Mild photothermal therapy/photodynamic therapy/chemotherapy of breast cancer by Lyp-1 modified Docetaxel/IR820 Co-loaded micelles

Cited by 216 publications

References 28 publications

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

Near-infrared light-triggered theranostics for tumor-specific enhanced multimodal imaging and photothermal therapy

Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells

Contact Info

Product

Resources

About